Ocular Therapeutix, Inc.

OTX-DED(dexamethasone intracanalicular insert)

SUSTAINED-RELEASE PRODUCT CANDIDATE TO TREAT EPISODIC DRY EYE

Our newest product candidate, OTX-DED, is a low dose, intracanalicular insert of dexamethasone for the treatment of patients with episodic dry eye disease. OTX-DED is designed to release dexamethasone over a period of two to three weeks for the short-term treatment of the signs and symptoms of dry eye disease.¹

Many dry eye patients experience exacerbations of their signs and symptoms likely related to inflammation.³ Currently available topical ophthalmic steroids have preservatives^4-8 which can result in ocular surface toxicity.⁹ These drops may also lead to adverse events such as elevated IOP or increased risk of infection if used chronically.¹⁰ OTX-DED may offer these patients the opportunity to be treated with a non-abusable, physician-administered, preservative-free and hands-free steroid therapy.¹

EXISTING TREATMENTS

Slow onset of action^3,11

Burning/stinging upon application^11,12

Topical ophthalmic steroids can be misused¹³

Contain preservatives^4-8 which may cause ocular toxicity⁹